Abstract
Background: The current treatment for allergic rhinitis (AR) is inadequate. Objective: The present study aimed to investigate the therapeutic effect of taurine on AR and to identify the underlying molecular mechanisms. Methods: The serum level of the antioxidant enzyme extracellular superoxide dismutase (SOD3) was determined in AR patients and in healthy controls. The antiallergic inflammatory effects of taurine were evaluated in a dinitrophenyl-human serum albumin (DNP-HSA)-stimulated human mast cell line (HMC-1) and in an ovalbumin (OVA)-induced AR mouse model. Results: Clinically, a reduction in serum level of SOD3 was observed in AR patients. Taurine treatment led to dose-dependent increases in SOD3 at both protein and mRNA levels in HMC-1 cells. SOD3 production was regulated by peroxisome proliferator-activated receptor-γ (PPAR-γ) in response to taurine. SOD3 overexpression inhibited the release of proinflammatory cytokines including tumor necrosis factor-α (, interleukin (IL)-4, and IL-6. Its overexpression also ameliorated the loss of interferon-γ. SOD3 and PPAR-γ influenced inflammatory cytokine production via regulation of the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2). An OVA-induced AR animal model study showed that taurine was efficacious in alleviating allergic inflammatory reactions by relieving behavior symptoms of AR mice and reducing eosinophilic and mast cell infiltration into the nasal cavity. In addition, taurine treatment increased the production of SOD3 and PPAR-γ, which, in turn, suppressed expression of proinflammatory cytokines through phosphorylation of ERK1/2. Conclusion: Taurine could potentially serve as a therapeutic treatment for allergic disorders.
References
1.
Togias
AG
. Systemic immunologic and inflammatory aspects of allergic rhinitis
. J Allergy Clin Immunol
. 2000
Nov
;106
(5
Suppl
):S247
–50
.
[PubMed]
0091-67492.
Asher
MI
, Montefort
S
, Björkstén
B
, Lai
CK
, Strachan
DP
, Weiland
SK
, et al.; ISAAC Phase Three Study Group
. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys
. Lancet
. 2006
Aug
;368
(9537
):733
–43
.
[PubMed]
0140-67363.
4.
Kappen
JH
, Durham
SR
, Veen
HI
, Shamji
MH
. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma
. Ther Adv Respir Dis
. 2017
Jan
;11
(1
):73
–86
.
[PubMed]
1753-46585.
Bowler
RP
, Crapo
JD
. Oxidative stress in allergic respiratory diseases
. J Allergy Clin Immunol
. 2002
Sep
;110
(3
):349
–56
.
[PubMed]
0091-67496.
7.
Bowler
RP
, Crapo
JD
. Oxidative stress in airways: is there a role for extracellular superoxide dismutase?
Am J Respir Crit Care Med
. 2002
Dec
;166
(12 Pt 2
supplement_1
):S38
–43
.
[PubMed]
1073-449X8.
Kwon
MJ
, Jeon
YJ
, Lee
KY
, Kim
TY
. Superoxide dismutase 3 controls adaptive immune responses and contributes to the inhibition of ovalbumin-induced allergic airway inflammation in mice
. Antioxid Redox Signal
. 2012
Nov
;17
(10
):1376
–92
.
[PubMed]
1523-08649.
Mangelsdorf
DJ
, Thummel
C
, Beato
M
, Herrlich
P
, Schütz
G
, Umesono
K
, et al. The nuclear receptor superfamily: the second decade
. Cell
. 1995
Dec
;83
(6
):835
–9
.
[PubMed]
0092-867410.
Tontonoz
P
, Hu
E
, Spiegelman
BM
. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
. Cell
. 1994
Dec
;79
(7
):1147
–56
.
[PubMed]
0092-867411.
Chinetti
G
, Griglio
S
, Antonucci
M
, Torra
IP
, Delerive
P
, Majd
Z
, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
. J Biol Chem
. 1998
Oct
;273
(40
):25573
–80
.
[PubMed]
0021-925812.
Gelman
L
, Fruchart
JC
, Auwerx
J
. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
. Cell Mol Life Sci
. 1999
Jun
;55
(6-7
):932
–43
.
[PubMed]
1420-682X13.
Ricote
M
, Li
AC
, Willson
TM
, Kelly
CJ
, Glass
CK
. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
. Nature
. 1998
Jan
;391
(6662
):79
–82
.
[PubMed]
0028-083614.
Woerly
G
, Honda
K
, Loyens
M
, Papin
JP
, Auwerx
J
, Staels
B
, et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation
. J Exp Med
. 2003
Aug
;198
(3
):411
–21
.
[PubMed]
0022-100715.
Honda
K
, Marquillies
P
, Capron
M
, Dombrowicz
D
. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model
. J Allergy Clin Immunol
. 2004
May
;113
(5
):882
–8
.
[PubMed]
0091-674916.
Chao
CT
, Huang
JW
, Chiang
CK
, Chen
YC
, Fang
CC
, Hu
FC
, et al. Diabetes mellitus, superoxide dismutase and peroxisome proliferator activated receptor gamma polymorphisms modify the outcome of end-stage renal disease patients of Han Chinese origin
. Nephrology (Carlton)
. 2018
Feb
;23
(2
):117
–25
.
[PubMed]
1320-535817.
Ripps
H
, Shen
W
. Review: taurine: a “very essential” amino acid
. Mol Vis
. 2012
;18
:2673
–86
.
[PubMed]
1090-053518.
Li
S
, Guan
H
, Qian
Z
, Sun
Y
, Gao
C
, Li
G
, et al. Taurine inhibits 2,5-hexanedione-induced oxidative stress and mitochondria-dependent apoptosis in PC12 cells
. Ind Health
. 2017
Apr
;55
(2
):108
–18
.
[PubMed]
0019-836619.
Grimble
RF
. Sulphur amino acids and the metabolic response to cytokines
. Adv Exp Med Biol
. 1994
;359
:41
–9
.
[PubMed]
0065-259820.
Ito
T
, Schaffer
SW
, Azuma
J
. The potential usefulness of taurine on diabetes mellitus and its complications
. Amino Acids
. 2012
May
;42
(5
):1529
–39
.
[PubMed]
0939-445121.
Marcinkiewicz
J
, Kontny
E
. Taurine and inflammatory diseases
. Amino Acids
. 2014
Jan
;46
(1
):7
–20
.
[PubMed]
0939-445122.
Chen
G
, Nan
C
, Tian
J
, Jean-Charles
P
, Li
Y
, Weissbach
H
, et al. Protective effects of taurine against oxidative stress in the heart of MsrA knockout mice
. J Cell Biochem
. 2012
Nov
;113
(11
):3559
–66
.
[PubMed]
0730-231223.
Su
WY
, Folz
R
, Chen
JS
, Crapo
JD
, Chang
LY
. Extracellular superoxide dismutase mRNA expressions in the human lung by in situ hybridization
. Am J Respir Cell Mol Biol
. 1997
Feb
;16
(2
):162
–70
.
[PubMed]
1044-154924.
Oury
TD
, Chang
LY
, Marklund
SL
, Day
BJ
, Crapo
JD
. Immunocytochemical localization of extracellular superoxide dismutase in human lung
. Lab Invest
. 1994
Jun
;70
(6
):889
–98
.
[PubMed]
0023-683725.
Iijima
MK
, Kobayashi
T
, Kamada
H
, Shimojo
N
. Exposure to ozone aggravates nasal allergy-like symptoms in guinea pigs
. Toxicol Lett
. 2001
Aug
;123
(1
):77
–85
.
[PubMed]
0378-427426.
Schuller-Levis
GB
, Park
E
. Taurine and its chloramine: modulators of immunity
. Neurochem Res
. 2004
Jan
;29
(1
):117
–26
.
[PubMed]
0364-319027.
Green
TR
, Fellman
JH
, Eicher
AL
, Pratt
KL
. Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils
. Biochim Biophys Acta
. 1991
Jan
;1073
(1
):91
–7
.
[PubMed]
0006-300228.
Nam
SY
, Kim
HM
, Jeong
HJ
. The potential protective role of taurine against experimental allergic inflammation
. Life Sci
. 2017
Sep
;184
:18
–24
.
[PubMed]
0024-320529.
Kim
SR
, Lee
KS
, Park
HS
, Park
SJ
, Min
KH
, Jin
SM
, et al. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma
. Mol Pharmacol
. 2005
Dec
;68
(6
):1568
–75
.
[PubMed]
0026-895X30.
Lee
KS
, Park
SJ
, Hwang
PH
, Yi
HK
, Song
CH
, Chai
OH
, et al. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN
. FASEB J
. 2005
Jun
;19
(8
):1033
–5
.
[PubMed]
0892-663831.
Lee
YC
, Lee
KS
, Park
SJ
, Park
HS
, Lim
JS
, Park
KH
, et al. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid
. FASEB J
. 2004
Dec
;18
(15
):1917
–9
.
[PubMed]
0892-6638© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
